About Penta
Who we are
Diversity and Inclusion
Our Network
Penta Foundation Italy
Penta ID Innovation
Annual reports
Our Activities
News & Events
News
Press center
Penta Newsletter
Stories
Scientific Views
Penta Aperitivo Webinars
Publications
Contact us
Work with us
Vacancies
Call for services
Brighter Future Award
Archivio
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial
Dolutegravir-based HIV treatment is better for babies and young children
Probability of AIDS and non-AIDS-related mortality of early-treated children living with HIV-1
Joint evolution of CD4 and viral load trajectories over 2 years in an early-treated pediatric African cohort
Healthy dynamics of CD4 T cells may drive HIV resurgence in perinatally-infected infants on antiretroviral therapy
Incidence of SARS-CoV-2 infection and clinical characteristics in children and young people living with HIV in Europe
SARS-CoV-2 infections in infants in Haiti 2020– 2021; evidence from a seroepidemiological cohort
Incidence of SARS-CoV-2 infection and clinical characteristics in children and young people living with HIV in Europe
Registrations are open for the PentaTr@ining course: ‘Fungal Infections in Paediatrics’
CARMA Global sites prepared and ready to enrol
Population pharmacokinetics of unbound and total plasma dolutegravir concentrations in children ≥ 12 years old: A pharmacokinetic sub-study of the SMILE trial-PENTA17-ANRS 152
Effect of dolutegravir on folate and vitamin B12 status among HIV- infected children and adolescents in the ODYSSEY trial
The subphenotypes of early-treated children living with HIV-1
ZIKAction paediatric registry: maternal characteristics and clinical, radiological, and follow-up features of children born with congenital zika infection in brazil